Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)

Chimeric antigen receptor (CAR)-expressing T-cells are without a doubt a breakthrough therapy for hematological malignancies. Despite their success, clinical experience has revealed several challenges, which include relapse after targeting single antigens such as CD19 in the case of B-cell acute lym...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitwasi, Nicola, Arndt, Claudia, Loureiro, Liliana R., Kegler, Alexandra, Fasslrinner, Frederick, Berndt, Nicole, Bergmann, Ralf, Hořejší, Vaclav, Rössig, Claudia, Bachmann, Michael, Feldmann, Anja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105388/
https://www.ncbi.nlm.nih.gov/pubmed/35563312
http://dx.doi.org/10.3390/ijms23094920

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105388/
https://www.ncbi.nlm.nih.gov/pubmed/35563312
http://dx.doi.org/10.3390/ijms23094920

Ejemplares similares